Last €30.61 EUR
Change Today +1.77 / 6.14%
Volume 294.6K
ALCLS On Other Exchanges
Symbol
Exchange
EN Paris
Frankfurt
OTC US
As of 11:38 AM 02/26/15 All times are local (Market data is delayed by at least 15 minutes).

cellectis (ALCLS) Snapshot

Open
€29.00
Previous Close
€28.84
Day High
€30.67
Day Low
€28.20
52 Week High
02/26/15 - €30.67
52 Week Low
03/3/14 - €4.43
Market Cap
900.5M
Average Volume 10 Days
221.6K
EPS TTM
€-3.01
Shares Outstanding
29.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CELLECTIS (ALCLS)

Related News

No related news articles were found.

cellectis (ALCLS) Related Businessweek News

No Related Businessweek News Found

cellectis (ALCLS) Details

Cellectis, a biopharmaceutical company, develops cancer products based on engineered T cells armed with a chimeric antigen receptor for the treatment of liquid and solid tumors. Its lead product candidate, UCART19, is an allogeneic engineered T cell product for the treatment of CD19 expressing hematologic malignancies that developed in chronic lymphocytic leukemia and acute lymphoblastic leukemia indications. The company’s products also include hematopoietic tumors, such as UCART123 and UCART33 for acute myeloid leukemia indications, and UCART-BCMA and UCART38 for multiple myeloma indications, as well as solid tumors comprising UCART5T4 for various solid tumor indications and UCART-EgfrVIII for glioblastoma indications. In addition, it is focused on life sciences to build products based on genome engineering technologies in various fields and markets. Cellectis was founded in 1999 and is based in Paris, France.

193 Employees
Last Reported Date: 04/30/14
Founded in 1999

cellectis (ALCLS) Top Compensated Officers

Co-Founder, Chairman and Chief Executive Offi...
Total Annual Compensation: €328.4K
Co-Founder, Executive Vice President of Corpo...
Total Annual Compensation: €248.8K
Compensation as of Fiscal Year 2013.

cellectis (ALCLS) Key Developments

Cellectis Seeks Acquisitions

Cellectis S.A. (ENXTPA:ALCLS) is looking for acquisition opportunities. Cellectis has filed a follow-on equity offering in the amount of $115 million and may use a portion of the net proceeds to acquire, license or invest in complementary products, technologies or businesses.

Cellectis SA Enters into Exclusive Licensing Agreement with the Ohio State University

Cellectis SA announced it has entered into an exclusive licensing agreement with the Ohio State University for development and distribution of chimeric antigen receptor (CAR) technology targeting multiple myeloma cells.

Cellectis Mulls IPO

Cellectis (ENXTPA:ALCLS) announced that it plans to conduct a registered initial public offering (IPO) in the United States. The timing, number of shares and price of the proposed offering have not yet been determined.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALCLS:FP €30.61 EUR +1.77

ALCLS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cellular Dynamics International Inc $5.70 USD +0.56
General Electric Co $25.89 USD -0.02
Lonza Group AG SFr.117.10 CHF -0.50
Sigma-Aldrich Corp $138.06 USD -0.01
View Industry Companies
 

Industry Analysis

ALCLS

Industry Average

Valuation ALCLS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 21.9x
Price/Book 29.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 26.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELLECTIS, please visit www.cellectis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.